Study guide
5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications
AACN Cardiac Medicine Certification CMC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview and the CMC Test Plan
1.1 CMC Exam Format, Eligibility, Fees & Scoring 1.2 The CMC Test Plan: Four Domains and How to Study Them
2 Chapter 2: Acute Coronary Syndromes and Ischemic Heart Disease
2.1 Pathophysiology & Classification of Acute Coronary Syndromes 2.2 12-Lead ECG Localization & Cardiac Biomarker Trajectories 2.3 Acute Reperfusion Strategies & Nursing Management 2.4 Complications of Acute Myocardial Infarction 2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy
3 Chapter 3: Heart Failure, Cardiomyopathies, Pericardial and Valvular Disease
3.1 Acute Decompensated Heart Failure & Staging 3.2 Acute Cardiogenic Pulmonary Edema 3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies 3.4 Acute Pericarditis, Cardiac Tamponade & Constrictive Pericarditis 3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease 3.6 Valvular Heart Disease: Stenosis & Regurgitation 3.7 Syncope: Cardiac Versus Non-Cardiac Causes and Workup
4 Chapter 4: Dysrhythmias, Conduction Disorders and Electrophysiologic Interventions
4.1 Atrial Fibrillation, Atrial Flutter & Supraventricular Tachycardias 4.2 Ventricular Arrhythmias & Cardiac Arrest Management 4.3 Atrioventricular Blocks & Intraventricular Conduction Delays 4.4 Temporary Pacing: Transcutaneous, Transvenous and Epicardial 4.5 Permanent Pacemakers, CRT and Device Troubleshooting 4.6 Implantable and Wearable Cardioverter Defibrillators 4.7 Catheter Ablation and Post-Ablation Nursing Care 4.8 Synchronized Cardioversion and Defibrillation
5 Chapter 5: Vascular Conditions and Vascular Interventions
5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises 5.2 Peripheral Artery Disease & Acute Limb Ischemia 5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis 5.4 Peripheral and Carotid Angiography and Interventions 5.5 Endovascular Aortic Repair: EVAR and TEVAR 5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications
6 Chapter 6: Shock States and Mechanical Circulatory Support
6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies 6.2 Non-Cardiogenic Shock: Hypovolemic, Distributive and Obstructive 6.3 Multisystem Organ Dysfunction Syndrome 6.4 Intra-Aortic Balloon Pump Therapy & Waveform Optimization 6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD
7 Chapter 7: Cardiac Procedures and Structural Heart Interventions
7.1 Diagnostic Cardiac Catheterization & Coronary Angiography Interpretation 7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care 7.3 Structural Heart Interventions: TAVR, MitraClip, Pericardiocentesis 7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications
8 Chapter 8: Cardiovascular Pharmacology
8.1 Inotropes, Vasopressors & Inodilators 8.2 Vasodilators & Antianginal Agents 8.3 Antiarrhythmic Agents: Vaughan Williams Classes I-IV 8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents 8.5 Diuretics and Decongestion Strategies 8.6 Guideline-Directed Medical Therapy for Heart Failure
9 Chapter 9: Non-Cardiovascular Conditions: Pulmonary
9.1 Acute Pulmonary Embolism 9.2 Acute Respiratory Failure and ARDS 9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax 9.4 Pulmonary Hypertension and Right Ventricular Failure 9.5 Sleep-Disordered Breathing in Cardiac Patients
10 Chapter 10: Non-Cardiovascular Conditions: Endocrine, Renal, Hematologic, Neurologic and Behavioral
10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care 10.2 Thyroid and Adrenal Disorders in the Cardiac Patient 10.3 Metabolic Syndrome and Cardiometabolic Risk 10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders 10.5 Anemia and Transfusion Management in Cardiac Patients 10.6 Acute Ischemic and Hemorrhagic Stroke in the Cardiac Patient 10.7 Acute Kidney Injury and Contrast-Associated Nephropathy 10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient 10.9 Electrolyte Imbalances and Dysrhythmia Risk 10.10 Substance Use, Withdrawal and Cardiac Effects 10.11 Non-Cardiac Chest Pain: Differential and Triage 10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients
11 Chapter 11: Monitoring and Diagnostics
11.1 Pulmonary Artery Catheterization & Hemodynamic Waveform Interpretation 11.2 Arterial Line Monitoring, Continuous Cardiac Output & ScvO2 11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging 11.4 Stress Testing and Myocardial Perfusion Imaging 11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices 11.6 Laboratory Testing in Cardiac Care 11.7 Arterial Blood Gases and Acid-Base Interpretation 11.8 Pulse Oximetry, Capnography and Chest Radiography
12 Chapter 12: Respiratory, Renal and Multisystem Therapeutic Interventions
12.1 Non-Invasive Ventilation in Cardiac Patients 12.2 Invasive Mechanical Ventilation and Heart-Lung Interactions 12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration 12.4 Targeted Temperature Management After Cardiac Arrest 12.5 Palliative and End-of-Life Care in Advanced Cardiac Disease
5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications
Key Takeaways Explain This Topic AI
Catheter-directed thrombolysis embeds a multi-side-hole catheter inside the thrombus and infuses alteplase at roughly 0.5-1 mg/hour per catheter with no systemic bolus, so total lytic exposure is often 10-24 mg rather than the 100 mg systemic dose.
Fibrinogen is the lytic safety lab: a value below about 150 mg/dL, or a fall of more than 50% from baseline, triggers rate reduction or discontinuation. Check fibrinogen, hemoglobin, platelets and aPTT every 4-6 hours and perform hourly neurologic checks.
Retroperitoneal hemorrhage follows a femoral puncture above the inguinal ligament and presents with flank or back pain, unexplained hypotension and tachycardia and a falling hemoglobin, while the groin looks clean and the abdomen stays soft.
A pulsatile groin mass with a systolic bruit and a to-and-fro Doppler signal is a pseudoaneurysm treated with ultrasound-guided compression or thrombin injection; a continuous machinery-like bruit without a pulsatile mass is an arteriovenous fistula.
The femoral arteriotomy sits 1-2 cm cephalad to the skin nick, so compressing the skin puncture instead of the arteriotomy is the classic reason a hematoma keeps expanding despite apparently adequate pressure.
Last updated: August 2026
Catheter-Directed Thrombolysis: One Technique, Three Territories
The principle is dose localization. Instead of a systemic 100 mg alteplase dose distributed to every healed wound in the body, a multi-side-hole infusion catheter is embedded directly within the thrombus and delivers a low-rate infusion with no systemic bolus , concentrating drug where fibrin is and limiting systemic fibrinogenolysis. The CMC exam treats catheter-directed thrombolysis (CDT) as a monitoring assignment, not a procedure.
Indications by Territory
Territory Who gets CDT Alternatives and adjuncts
Arterial — acute limb ischemia Rutherford class I (viable) and class IIa (marginally threatened) limbs: sensory loss absent or limited to the toes, no motor deficit, and a limb that can tolerate the hours lysis requires Class IIb (motor weakness, sensory loss beyond the toes) requires immediate revascularization by surgical embolectomy or percutaneous mechanical thrombectomy, because lysis is too slow. Class III (rigor, fixed mottling, absent arterial and venous Doppler) is irreversible: primary amputation, not lysis
Venous — iliofemoral DVT Symptoms under 14 days, severe symptoms, low bleeding risk, good functional status and life expectancy; phlegmasia cerulea dolens is the strongest indication Pharmacomechanical thrombectomy. Routine lysis of ordinary femoropopliteal DVT is not supported (ATTRACT)
Pulmonary — pulmonary embolism Intermediate-high-risk PE (right ventricular strain on echo or CT plus a positive troponin) that is deteriorating, and high-risk (massive) PE when systemic lysis has failed or is contraindicated Systemic alteplase 100 mg over 2 hours when catheter therapy is unavailable; large-bore mechanical/aspiration thrombectomy; surgical embolectomy; VA-ECMO as a bridge. Decisions increasingly route through a pulmonary embolism response team (PERT)
Technique Variants
Standard CDT — a plain multi-side-hole infusion catheter left in the clot for hours.
Ultrasound-assisted CDT — high-frequency, low-power ultrasound loosens fibrin strands and exposes plasminogen receptors. Regimens are deliberately low dose and short, on the order of 1 mg/hour per catheter for the first several hours followed by 0.5 mg/hour, with total doses commonly around 10-24 mg.
Pharmacomechanical thrombectomy — lytic plus aspiration or maceration in a single sitting, which shortens or eliminates the ICU infusion entirely.
Mechanical or aspiration thrombectomy alone — no lytic at all. This is the option when bleeding risk forbids thrombolysis, such as recent surgery, recent stroke, or active bleeding.
Contraindications
Absolute: any prior intracranial hemorrhage; known cerebral vascular malformation or malignant intracranial neoplasm; ischemic stroke within 3 months; active internal bleeding; suspected aortic dissection; significant closed head or facial trauma within 3 months; intracranial or intraspinal surgery within 2 months.
Relative: uncontrolled hypertension above 180/110 mmHg; current anticoagulation with a supratherapeutic INR; major surgery within 3 weeks or internal bleeding within 2-4 weeks; traumatic or prolonged CPR; non-compressible vascular puncture; pregnancy; active peptic ulcer disease; advanced age; known bleeding diathesis.
Monitoring the Infusion
Parameter Frequency Action threshold
Fibrinogen every 4-6 hours Below about 150 mg/dL, or a fall greater than 50% from baseline: reduce the rate or stop per protocol
Hemoglobin and hematocrit every 4-6 hours Any unexplained fall means occult bleeding until proven otherwise, especially retroperitoneal
Platelet count every 6-12 hours Below 100,000/microL: notify; consider HIT if heparin is running
aPTT or anti-Xa per the concurrent heparin protocol Subtherapeutic heparin risks pericatheter thrombosis; supratherapeutic compounds bleeding risk
Neurologic examination hourly Any new headache, confusion, focal deficit or seizure: stop the lytic immediately and obtain a stat non-contrast head CT
Puncture site and dressing every 15-60 minutes Oozing, expanding hematoma, or increasing site pain
Distal perfusion (arterial cases) hourly with Doppler Return of a signal indicates success; a worsening signal indicates failed lysis or distal embolization
Stopping rules the nurse enacts: any suspected intracranial hemorrhage, major overt bleeding, new hemodynamic instability, or a critically low fibrinogen. Immediate management of major bleeding on a lytic is to stop the alteplase and the heparin, apply direct pressure, resuscitate with crystalloid and blood products, send fibrinogen and a type and crossmatch, and give cryoprecipitate to replace fibrinogen plus fresh frozen plasma, with tranexamic acid or aminocaproic acid as the antifibrinolytic and platelets if the patient is thrombocytopenic or on antiplatelet agents.